Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01016054 · ClinicalTrials.gov registry record · Phase 1
A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer
A Phase 1 study, sponsored by Astellas Pharma.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT01016054 is a Phase 1 study that was terminated before completion, run by Astellas Pharma. The registered enrollment target is 4 participants.
The verdict
NCT01016054, a Phase 1 study, was terminated before completion, sponsored by Astellas Pharma.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This is a parallel arm study to evaluate AGS-8M4 administered in combination with chemotherapy in subjects with ovarian cancer. AGS-8M4 will be administered as an IV infusion until disease worsens.
Interventions
- DRUG carboplatin
- DRUG gemcitabine
- DRUG Pegylated liposomal doxorubicin (PLD)
- BIOLOGICAL AGS-8M4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2009-10 |
| Est. Completion | 2010-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01016054
The ClinicalTrials.gov registry entry for NCT01016054 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which carboplatin is the first listed.
NCT01016054 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01016054 about?
NCT01016054 is a clinical study titled "A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer". This is a parallel arm study to evaluate AGS-8M4 administered in combination with chemotherapy in subjects with ovarian cancer. AGS-8M4 will be administered as an IV infusion until disease worsens.
What is the current status of trial NCT01016054?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2009-10. Estimated completion is 2010-04.
What interventions are being tested in trial NCT01016054?
The interventions under investigation include: carboplatin (DRUG), gemcitabine (DRUG), Pegylated liposomal doxorubicin (PLD) (DRUG), AGS-8M4 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01016054?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.